Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Common Equity: 2021-2025

Historic Common Equity for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $147.7 million.

  • ARS Pharmaceuticals' Common Equity fell 26.53% to $147.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.7 million, marking a year-over-year decrease of 26.53%. This contributed to the annual value of $256.8 million for FY2024, which is 11.28% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Common Equity is $147.7 million, which was down 23.22% from $192.3 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Common Equity ranged from a high of $368.5 million in Q1 2021 and a low of -$31.3 million during Q4 2021.
  • Its 3-year average for Common Equity is $222.1 million, with a median of $229.0 million in 2025.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 972.70% in 2022, then dropped by 26.53% in 2025.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Common Equity stood at -$31.3 million in 2021, then soared by 972.70% to $272.9 million in 2022, then decreased by 15.44% to $230.8 million in 2023, then climbed by 11.28% to $256.8 million in 2024, then dropped by 26.53% to $147.7 million in 2025.
  • Its Common Equity was $147.7 million in Q3 2025, compared to $192.3 million in Q2 2025 and $229.0 million in Q1 2025.